Sermorelin FDA Approval History

What Is Sermorelin Acetate?

Sermorelin acetate is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It acts on the anterior pituitary gland to stimulate the synthesis and secretion of endogenous growth hormone (GH). Unlike exogenous GH injections, sermorelin preserves the body's natural feedback loops, meaning the pituitary retains control over how much GH enters circulation.

Pharmacologic Classification

The FDA classifies sermorelin as a GHRH analog. Its mechanism differs from growth hormone secretagogues like ipamorelin or MK-677, which act on the ghrelin receptor (GHS-R1a). Sermorelin binds directly to the GHRH receptor on somatotroph cells in the anterior pituitary 1. This distinction matters for regulatory purposes: sermorelin was evaluated as a diagnostic and therapeutic agent specifically for GH axis function, not as a broader metabolic drug.

Why the Regulatory History Matters

Patients and clinicians frequently encounter confusion about sermorelin's legal status. Because the branded product (Geref) is no longer on the market, some assume the drug was recalled for safety reasons. That assumption is incorrect. Understanding the full regulatory timeline clarifies why sermorelin remains a legitimate prescription medication available through compounding.

The Path to FDA Approval (1985-1997)

Sermorelin's regulatory journey spanned more than a decade, beginning with early clinical investigations in the mid-1980s and culminating in a 1997 approval.

Early Clinical Development

Research into GHRH analogs accelerated after the identification and sequencing of human GHRH in 1982. By 1985, investigators at multiple academic centers were conducting open-label trials of sermorelin (GHRH 1-29 NH2) in children with idiopathic growth hormone deficiency. Walker and colleagues published a key 6-month study demonstrating that twice-daily subcutaneous sermorelin injections significantly increased growth velocity in GH-deficient children, with mean growth rates rising from 3.6 cm/year to 8.2 cm/year 1.

NDA Submission and Approval

EMD Serono (then Serono Laboratories) filed a New Drug Application (NDA 020604) with the FDA. The agency approved two formulations:

• Geref Diagnostic (sermorelin acetate for injection, 50 mcg): approved for evaluating pituitary GH secretory capacity in patients with suspected GH deficiency.
• Geref (sermorelin acetate for injection, multidose vials): approved for the treatment of idiopathic growth hormone deficiency in children with growth failure who have documented GH deficiency by provocative testing.

The 1997 approval was based on clinical trial data showing statistically significant improvements in linear growth velocity compared to baseline in GH-deficient pediatric populations. The FDA's review noted that sermorelin offered a physiologic alternative to recombinant GH by acting through the body's own pituitary axis 2.

Labeling at Approval

The original Geref label specified the following key elements:

• Indication: long-term treatment of children with idiopathic growth hormone deficiency as determined by a subnormal response to at least two standard GH provocative tests.
• Dosing: 30 mcg/kg body weight subcutaneously once daily at bedtime.
• Contraindications: known hypersensitivity to sermorelin or any excipient; active malignancy (due to theoretical concern about GH-mediated tumor growth).
• Warnings: patients receiving sermorelin required periodic monitoring of IGF-1 and growth velocity; antibody formation to sermorelin occurred in roughly 50% of patients by 12 months but did not consistently reduce clinical response.

Voluntary Market Withdrawal (2008)

In 2008, EMD Serono voluntarily withdrew Geref and Geref Diagnostic from the U.S. Market. The FDA's MedWatch database and the Federal Register confirm this withdrawal was for commercial reasons. It was not prompted by a safety signal.

Why the Branded Product Disappeared

Several factors drove the commercial decision. The pediatric GH deficiency market had shifted heavily toward recombinant human growth hormone (rhGH) products like Humatrope, Genotropin, and Norditropin. These offered direct GH replacement with predictable dose-response curves. Sermorelin, which required an intact pituitary to work, was a less attractive option for severe GH deficiency where pituitary function was compromised.

Sales of Geref had declined steadily throughout the 2000s. EMD Serono made a business decision to consolidate its portfolio. The FDA explicitly does not list sermorelin on its "Withdrawn for Safety" database, which catalogues drugs removed due to adverse events or efficacy concerns 3.

Impact on Prescribers and Patients

The withdrawal created a temporary gap in access. Clinicians who had been prescribing Geref needed to either switch patients to rhGH products or seek compounded sermorelin. Within months, 503A compounding pharmacies began filling the supply gap, compounding sermorelin acetate under individual patient prescriptions.

Current Regulatory Status: 503A Compounding

Today, sermorelin acetate is not available as an FDA-approved branded product. It is, however, legally available through 503A compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act.

How 503A Compounding Works

Under Section 503A, a licensed pharmacist may compound a medication for an individual patient based on a valid prescription from a licensed prescriber. The compounded product must use ingredients that meet USP or NF standards, and the pharmacy must comply with state pharmacy board regulations 4.

Key requirements for legally compounded sermorelin include:

• A valid, patient-specific prescription from a licensed provider.
• The compounding pharmacy must not essentially copy a commercially available product (since Geref is no longer marketed, this criterion is met).
• The active ingredient (sermorelin acetate) must appear on the FDA's list of bulk drug substances permitted for compounding, or not appear on the FDA's "withdrawn or removed" list.

503B Outsourcing Facility Considerations

Section 503B outsourcing facilities may also compound sermorelin for office use without individual prescriptions, provided they register with the FDA and comply with current Good Manufacturing Practice (cGMP) requirements. This pathway allows clinics to stock sermorelin for in-office administration or dispensing. The FDA has issued periodic guidance documents clarifying which bulk substances are permissible under 503B; sermorelin has remained available through this pathway 5.

Off-Label Use in Adults

The original FDA approval covered pediatric GH deficiency only. Adult use of sermorelin for age-related GH decline, body composition optimization, or sleep quality improvement is off-label. Off-label prescribing is legal and common across medicine; the American Medical Association estimates that approximately 21% of all prescriptions in the U.S. Are written for off-label indications.

Clinicians prescribing sermorelin to adults typically base their protocols on GH axis biomarkers (IGF-1, IGFBP-3) and clinical symptoms rather than FDA-approved labeling, since no branded label exists for this population.

Clinical Safety Profile

Sermorelin's safety record spans nearly four decades of clinical use. The adverse event profile documented in clinical trials and post-market experience is generally mild.

Common Adverse Reactions

In the original clinical trials submitted for NDA 020604, the most frequently reported adverse events were:

• Injection site reactions (pain, redness, swelling): reported in approximately 16% of pediatric subjects.
• Facial flushing: transient, occurring within minutes of injection in roughly 8% of patients.
• Headache: reported in approximately 6% of subjects.
• Nausea and abdominal discomfort: reported in approximately 3% of subjects.

No serious cardiovascular events, hepatotoxicity, or deaths were attributed to sermorelin in the key trials 1.

Antibody Formation

One notable finding from the registration trials was the development of anti-sermorelin antibodies. Approximately 50% of children treated for 12 months or longer developed detectable antibodies. The clinical significance was debated: some patients with high antibody titers showed attenuated GH responses, while others maintained normal growth velocity despite positive antibody tests 6.

This antibody concern was one factor that limited sermorelin's competitiveness against rhGH products, which do not carry the same immunogenicity profile at the pituitary stimulation level.

Post-Market Safety Data

After Geref's approval, the FDA's Adverse Event Reporting System (FAERS) collected limited post-market reports. The low volume of reports reflected both the drug's favorable safety profile and its relatively small market share compared to rhGH products. No FDA safety communications, boxed warnings, or Risk Evaluation and Mitigation Strategy (REMS) requirements were ever issued for sermorelin 7.

Contraindications and Precautions

The original label listed these contraindications, which remain relevant for compounded sermorelin:

• Active malignancy (GH stimulation could theoretically promote tumor growth).
• Known hypersensitivity to sermorelin acetate or mannitol (a common excipient).
• Pregnancy and lactation (Category C; no adequate human data).

Clinicians should also exercise caution in patients with hypothyroidism, since thyroid hormone is required for normal GH axis function, and in patients on glucocorticoids, which blunt the GH response to GHRH stimulation.

Sermorelin vs. Recombinant GH: Regulatory Distinctions

Understanding why sermorelin and recombinant GH occupy different regulatory spaces helps clarify prescribing decisions.

Mechanism-Level Differences

Recombinant GH (somatropin) directly replaces the hormone. The pituitary is bypassed entirely. Sermorelin, by contrast, signals the pituitary to produce and release GH through the normal secretory pathway, including pulsatile release patterns that mimic physiologic rhythms 8.

Regulatory Implications

Because recombinant GH is classified as a biologic, it falls under the Biologics License Application (BLA) pathway and is subject to more stringent manufacturing oversight. Sermorelin, as a small synthetic peptide (29 amino acids), was approved under the NDA pathway and is classified as a drug, not a biologic. This distinction affects:

• Manufacturing: synthetic peptide synthesis vs. Recombinant DNA technology.
• Compounding eligibility: small-molecule drugs are more readily compounded under 503A; biologics face additional restrictions.
• Cost: compounded sermorelin typically costs $100 to $300 per month, while branded rhGH products range from $800 to $3,000+ per month depending on dose and formulation.

Scheduling and Controlled Substance Status

Sermorelin is not a controlled substance under the Controlled Substances Act. It does not appear on any DEA schedule. This contrasts with GH itself, which is classified as a Schedule III controlled substance when prescribed for non-approved indications under the 1990 Anabolic Steroids Control Act (later amended in 2004). This scheduling distinction is one reason clinicians may prefer sermorelin for adult GH optimization: prescribing and dispensing carry fewer regulatory burdens than prescribing exogenous GH 9.

Key Regulatory Milestones: A Timeline

| Year | Event | |------|-------| | 1982 | Human GHRH identified and sequenced | | 1985-1990 | Phase I/II trials of sermorelin in GH-deficient children | | 1990 | Walker et al. Publish key 6-month efficacy data in Pediatrics | | 1997 | FDA approves Geref and Geref Diagnostic (NDA 020604) | | 2000-2007 | Market share declines as rhGH products dominate | | 2008 | EMD Serono voluntarily withdraws Geref from U.S. Market | | 2008-present | Sermorelin available via 503A/503B compounding pharmacies | | 2013 | FDA Drug Quality and Security Act (DQSA) codifies 503A and 503B pathways | | 2020-present | Growing off-label adult use for GH optimization, body composition, and sleep |

What the Label Said (and What It Means Today)

Since Geref is no longer marketed, the approved labeling is archived. Clinicians compounding sermorelin today reference the historical label for dosing guidance while adapting protocols to adult populations.

Pediatric Dosing (Original Label)

The approved dose was 30 mcg/kg subcutaneously once daily at bedtime. For a 30 kg child, that equals 900 mcg (0.9 mg) per injection. Bedtime dosing was chosen to align with the natural nocturnal GH surge.

Adult Dosing (Off-Label, Consensus-Based)

No FDA-approved adult dosing exists. Common clinical protocols use 200 to 300 mcg subcutaneously at bedtime, five to seven nights per week. Some providers cycle sermorelin (5 days on, 2 days off) to reduce antibody formation risk, though this approach lacks randomized trial support 10.

Monitoring typically includes baseline and follow-up IGF-1 levels at 6 to 12 week intervals, along with metabolic panels and fasting glucose to screen for GH-related insulin resistance.

Future Regulatory Outlook

Several developments could shift sermorelin's regulatory field in the coming years.

FDA Compounding Oversight

The FDA has increased scrutiny of compounding pharmacies since the 2012 New England Compounding Center (NECC) meningitis outbreak. Inspections of 503A and 503B facilities have intensified. Sermorelin compounders must demonstrate sterile technique, potency testing, and appropriate beyond-use dating. Any tightening of the FDA's bulk drug substance list could affect sermorelin availability, though no such action has been proposed as of May 2026.

Potential for New Clinical Trials

Interest in GHRH analogs for adult indications (sarcopenia, metabolic syndrome, traumatic brain injury recovery) has grown. If a pharmaceutical sponsor were to pursue a new NDA for sermorelin in an adult indication, the existing safety database from pediatric trials and decades of compounding use would support the application. No sponsor has publicly announced such plans.

Sermorelin's patent protection expired years ago, making it unlikely that any single company would invest in the estimated $50 to $100 million cost of a new NDA without exclusivity incentives. The 505(b)(2) pathway, which allows referencing existing data, could reduce this cost, but the commercial case remains uncertain given the availability of low-cost compounded product.